GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (BSP:B1GN34) » Definitions » Research & Development

BeiGene (BSP:B1GN34) Research & Development : R$9,910 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is BeiGene Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. BeiGene's Research & Development for the three months ended in Sep. 2024 was R$2,748 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was R$9,910 Mil.

BeiGene Research & Development Historical Data

The historical data trend for BeiGene's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Research & Development Chart

BeiGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,806.26 6,661.75 8,251.85 8,605.12 8,714.76

BeiGene Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,238.51 2,420.44 2,293.89 2,447.80 2,747.74

BeiGene Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$9,910 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeiGene  (BSP:B1GN34) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

BeiGene Research & Development Related Terms

Thank you for viewing the detailed overview of BeiGene's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (BSP:B1GN34) » Definitions » Research & Development
Comparable Companies
BNTX ALNY BMRN MRNA RPRX LEGN INCY UTHR SRPT TECH OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 HKSE:02269 XBRU:ARGX SZSE:300122 OCSE:GMAB
Traded in Other Exchanges
BEIGF:USA BGNE:USA 06160:Hong Kong 49B:Germany 688235:China
Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Website
https://www.beigene.com
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.

BeiGene Headlines

No Headlines